Influence of methylenetetrahydrofolate reductase gene polymorphisms on the outcome of pediatric patients with non-Hodgkin lymphoma treated with high-dose methotrexate. Issue 12 (December 2013)
- Record Type:
- Journal Article
- Title:
- Influence of methylenetetrahydrofolate reductase gene polymorphisms on the outcome of pediatric patients with non-Hodgkin lymphoma treated with high-dose methotrexate. Issue 12 (December 2013)
- Main Title:
- Influence of methylenetetrahydrofolate reductase gene polymorphisms on the outcome of pediatric patients with non-Hodgkin lymphoma treated with high-dose methotrexate
- Authors:
- D'Angelo, Velia
Ramaglia, Maria
Iannotta, Adriana
Francese, Matteo
Pota, Elvira
Affinita, Maria Carmen
Pecoraro, Giulia
Indolfi, Cristiana
Di Martino, Martina
Di Pinto, Daniela
Buffardi, Salvatore
Poggi, Vincenzo
Indolfi, Paolo
Casale, Fiorina - Abstract:
- <abstract> <title>Abstract</title> <p>High-dose methotrexate (MTX) is a key component of most treatment protocols for childhood and adolescent non-Hodgkin lymphoma (NHL). Recent studies have suggested that the toxicity of antifolate drugs, such as MTX, is affected by inherited single nucleotide polymorphisms (SNPs) in folate metabolizing genes. The aim of our study was to investigate the potential influence of the C677T and A1298C genetic variants of the methylenetetrahydrofolate reductase (MTHFR) gene on the clinical toxicity and efficacy of MTX in pediatric patients with NHL (<italic>n</italic> = 95) treated with therapeutic protocols Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) LNH-97 and EURO LB-02. We demonstrated that patients with the 677T genotype had an approximately six-fold greater risk of developing hematological toxicity compared with wild-type carriers, especially in the 1 g/m<sup>2</sup> treatment group (<italic>p</italic> = 0.01). Moreover, we identified a correlation between the risk of relapse and the T genotype: T carriers had reduced disease-free survival compared with wild-type patients (67% vs. 100%). Our data suggest a pharmacogenetic influence on the adverse effects of high-dose MTX in the 1 g/m<sup>2</sup> treatment group.</p> </abstract>
- Is Part Of:
- Leukemia & lymphoma. Volume 54:Issue 12(2013:Dec.)
- Journal:
- Leukemia & lymphoma
- Issue:
- Volume 54:Issue 12(2013:Dec.)
- Issue Display:
- Volume 54, Issue 12 (2013)
- Year:
- 2013
- Volume:
- 54
- Issue:
- 12
- Issue Sort Value:
- 2013-0054-0012-0000
- Page Start:
- 2639
- Page End:
- 2644
- Publication Date:
- 2013-12
- Subjects:
- Leukemia -- Periodicals
Lymphomas -- Periodicals
616.99419 - Journal URLs:
- http://informahealthcare.com ↗
- DOI:
- 10.3109/10428194.2013.784758 ↗
- Languages:
- English
- ISSNs:
- 1042-8194
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5185.251500
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 3860.xml